Tumor-targeted Gd-doped mesoporous Fe 3 O 4 nanoparticles for T 1 /T 2 MR imaging guided synergistic cancer therapy

Shaohui Zheng,Shang Jin,Min Jiao,Wenjun Wang,Xiaoyu Zhou,Jie Xu,Yong Wang,Peipei Dou,Zhen Jin,Changyu Wu,Jingjing Li,Xinting Ge,Kai Xu
DOI: https://doi.org/10.1080/10717544.2021.1909177
IF: 6.819
2021-01-01
Drug Delivery
Abstract:<span>In this study, a novel intelligent nanoplatform to integrate multiple imaging and therapeutic functions for targeted cancer theranostics. The nanoplatform, DOX@Gd-MFe<sub>3</sub>O<sub>4</sub> NPs, was constructed Gd-doped mesoporous Fe<sub>3</sub>O<sub>4</sub> nanoparticles following with the doxorubicin (DOX) loading in the mesopores of the NPs. The DOX@Gd-MFe<sub>3</sub>O<sub>4</sub> NPs exhibited good properties in colloidal dispersity, photothermal conversion, NIR triggered drug release, and high T<sub>1</sub>/T<sub>2</sub> relaxicity rate (<i>r</i><sub>1</sub>=9.64 mM<sup>−1</sup>s<sup>−1</sup>, <i>r</i><sub>2</sub>= 177.71 mM<sup>−1</sup>s<sup>−1</sup>). Benefiting from the high MR contrast, DOX@Gd-MFe<sub>3</sub>O<sub>4</sub> NPs enabled simultaneous T<sub>1</sub>/T<sub>2</sub> dual-modal MR imagining on 4T1 bearing mice <i>in vivo</i> and the MR contrast effect was further strengthened by external magnetic field. In addition, the DOX@Gd-MFe<sub>3</sub>O<sub>4</sub> NPs revealed the strongest inhibition to the growth of 4T1 <i>in vitro</i> and <i>in vivo</i> under NIR irradiation and guidance of external magnetic field. Moreover, biosafety was also validated by <i>in vitro</i> and <i>in vivo</i> tests. Thus, the prepared DOX@Gd-MFe<sub>3</sub>O<sub>4</sub> NPs would provide a promising intelligent nanoplatform for dual-modal MR imagining guided synergistic therapy in cancer theranostics.</span>
pharmacology & pharmacy
What problem does this paper attempt to address?